Longitudinal Immune Response to 3 Doses of Messenger RNA Vaccine Against Coronavirus Disease 2019 (COVID-19) in Pediatric Patients Receiving Chemotherapy for Cancer
Thomas Lehrnbecher, Ulrich Sack, Carsten Speckmann, Andreas H. Groll, Andreas Boldt, Benjamin Siebald, Simone Hettmer, Eva-Maria Demmerath, Judith Reemtsma, Barbara Schenk, Sandra Ciesek, Jan‐Henning Klusmann, Christian Jassoy, Sebastian Hoehl
Abstract
Our study in 21 pediatric cancer patients demonstrates that 3 doses of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) messenger RNA vaccine (BioNTech/Pfizer) elicited both humoral and cellular immunity in most patients during chemotherapy. Immunity was stronger in children with solid tumors and during maintenance therapy compared to those with hematological malignancies or during intensive chemotherapy. Clinical Trials Registration.ȃGerman Registry for Clinical Trials (DRKS00025254).
Topics & Concepts
MedicineChemotherapyImmune systemClinical trialImmunologyImmunityInduction chemotherapyCancerCellular immunityDiseaseInternal medicineCOVID-19 and healthcare impactsSARS-CoV-2 and COVID-19 ResearchCOVID-19 Clinical Research Studies